What is the standard of care for treating hyperkalemia in a skilled nursing facility?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Standard of Practice for Hyperkalemia Treatment in Skilled Nursing Facilities

In a skilled nursing facility, hyperkalemia management should follow a severity-based approach: immediate transfer to emergency care for severe hyperkalemia with ECG changes or K+ >6.5 mEq/L; for mild-moderate hyperkalemia (K+ 5.5-6.5 mEq/L), initiate potassium binders, optimize diuretics if volume overloaded, review and adjust (but avoid discontinuing) RAAS inhibitors, implement dietary modifications, and arrange close monitoring with repeat K+ levels within 1 week. 1

Severity Assessment and Initial Decision-Making

The first critical step is determining whether the patient requires emergency transfer versus SNF-based management:

  • Transfer to hospital immediately if:

    • K+ >6.5 mEq/L
    • Any ECG changes (peaked T-waves, widened QRS, loss of P-waves)
    • Rapid rise in potassium
    • Symptomatic (muscle weakness, palpitations, paresthesias)
  • Manage in SNF if:

    • K+ 5.5-6.5 mEq/L without ECG changes
    • Chronic, stable hyperkalemia
    • Patient clinically stable

1

SNF-Based Management Algorithm

Step 1: Confirm True Hyperkalemia

Before initiating treatment, rule out pseudohyperkalemia by:

  • Reviewing phlebotomy technique (avoid fist clenching, prolonged tourniquet time)
  • Checking for hemolysis
  • Repeating the test if any doubt exists
  • Remember plasma K+ runs 0.1-0.4 mEq/L lower than serum

1

Step 2: Identify and Address Reversible Causes

Review for precipitating factors:

  • Medications: NSAIDs, potassium supplements, potassium-sparing diuretics, trimethoprim, heparin
  • Acute illness: Fever, infection, dehydration, diarrhea (can paradoxically cause hyperkalemia in CKD)
  • Dietary indiscretion: Salt substitutes (potassium chloride), high-potassium foods
  • Recent medication changes: New RAAS inhibitor or dose increase

1

Step 3: Pharmacologic Management

Primary treatment: Potassium binders

  • Patiromer or sodium zirconium cyclosilicate (SZC) are preferred over older sodium polystyrene sulfonate (SPS)
  • SPS carries FDA warning for severe gastrointestinal adverse events including colonic necrosis and 33% mortality rate in some reports
  • Newer binders (patiromer, SZC) have demonstrated safety for up to 52 weeks in clinical trials
  • These agents allow continuation of RAAS inhibitors, which is critical for mortality reduction

1, 2, 3

Adjunctive measures based on clinical context:

  • Loop diuretics (furosemide): If patient has volume overload and preserved kidney function
  • Sodium bicarbonate: Only if concurrent metabolic acidosis present
  • Avoid empiric dietary restriction: Evidence for low-potassium diets is limited and may eliminate beneficial plant-based foods; instead focus on reducing non-plant potassium sources

1, 4

Step 4: RAAS Inhibitor Management - Critical Pitfall

Do NOT automatically discontinue RAAS inhibitors (ACE inhibitors, ARBs, MRAs) in response to hyperkalemia. This is a common error with serious consequences:

  • Discontinuation of RAAS inhibitors increases risk of mortality and major adverse cardiovascular events in patients with CKD (eGFR <30) and heart failure
  • These medications provide mortality benefit that outweighs hyperkalemia risk when properly managed
  • Instead: Treat the hyperkalemia with binders first, allowing continuation of life-saving therapy
  • Only consider dose reduction (not discontinuation) if hyperkalemia persists despite binder therapy
  • Reinitiate RAAS inhibitors after acute hyperkalemia resolves if previously discontinued

1, 5, 6

Step 5: Monitoring Protocol

Immediate monitoring:

  • Repeat K+ within 24-48 hours after initiating treatment
  • Weekly K+ checks until stable in normal range
  • Monitor for recurrence: 28-35% of patients experience recurrent hyperkalemia within 12 months

Long-term monitoring:

  • K+ levels before starting any RAAS inhibitor
  • Within 1 week of RAAS inhibitor initiation or dose increase
  • Regular monitoring based on CKD stage and risk factors
  • More frequent checks during acute illness, fever, or diarrhea

1, 3, 7

Common Pitfalls in SNF Setting

  1. Discontinuing RAAS inhibitors reflexively: This increases mortality risk in heart failure and CKD patients who benefit most from these medications 1, 6

  2. Over-relying on dietary restriction: Strict low-potassium diets are difficult to maintain, lack strong evidence, and eliminate heart-healthy foods. Focus dietary counseling on avoiding salt substitutes and excessive supplementation 1, 4

  3. Using sodium polystyrene sulfonate (SPS) as first-line: SPS has serious GI safety concerns and should be avoided when newer binders are available 1

  4. Failing to recognize chronic/recurrent nature: Hyperkalemia often recurs (30-35% within 12 months), requiring ongoing treatment rather than episodic management 3, 7

  5. Inadequate staff education: SNF staff need specific training on when to call providers, recognizing symptoms, and understanding the importance of continuing RAAS inhibitors 8

Real-World Context for SNFs

The SNF population faces unique challenges: elderly patients with multiple comorbidities (CKD, heart failure, diabetes), polypharmacy, and limited access to specialty care. Recent real-world data shows that only 51.5% of eligible patients receive RAAS inhibitors despite having CKD or heart failure, often due to hyperkalemia concerns. Conservative "watch and wait" approaches are common but lead to suboptimal outcomes. 2, 7

The paradigm shift: With availability of effective potassium binders (patiromer, SZC), SNFs can now maintain patients on guideline-directed RAAS inhibitor therapy while controlling hyperkalemia, improving both cardiovascular and renal outcomes. 2, 3, 5

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.